|Bid||4.00 x 1000|
|Ask||7.85 x 1000|
|Day's Range||6.18 - 6.29|
|52 Week Range||3.34 - 10.53|
|Beta (3Y Monthly)||2.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The ratings on eight P&I classes were affirmed because the transaction's key metrics, including Moody's loan-to-value (LTV) ratio, Moody's stressed debt service coverage ratio (DSCR) and the transaction's Herfindahl Index (Herf), are within acceptable ranges. The rating on the IO class was affirmed based on the credit quality of the referenced classes. The rating on Cl. PEZ was affirmed due to the credit quality of the referenced exchangeable classes.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is a pleasure to report that the Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is up 58% in the last quarter. But...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...
The Cambridge-based company announced after the stock market closed Thursday that it is discontinuing work on its sole drug candidate in clinical trials.
Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.
The biotech said it has also "retained external advisors to explore strategic alternatives," suggesting it may consider a sale.
On Wednesday, Nov. 7, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings ...
Merrimack, which focuses on therapies for biomarker-defined cancer, said it has terminated a study dubbed SHERLOC, which evaluated its MM-121 in combination with docetaxel in patients with heregulin-positive non-small cell lung cancer, or NSCLC. Docetaxel is a chemotherapy medication used to treat several cancers, including breast cancer, head and neck cancer, prostate cancer and NSCLC.
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.
Two former employees of rival biopharmaceutical companies were convicted on Tuesday on U.S. charges that they used their access to confidential information about drug studies to profit in the stock market through insider trading. A federal jury in Boston found Schultz Chan, a former Akebia Therapeutics Inc employee, and Songjiang Wang, who worked at Merrimack Pharmaceuticals Inc, guilty on conspiracy and securities fraud charges. Prosecutors said that from 2013 to 2014, Wang, Merrimack's director of statistical programming, tipped his friend Chan, 54, three times about positive results in drug studies before the Cambridge, Massachusetts-based company announced them.
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.
A former Akebia Therapeutics Inc (AKBA.O) employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday. U.S. District Judge Indira Talwani in Boston ordered the detention of Schultz Chan, who has had prior issues following court directives, after asking why he could not heed her warnings to not talk to witnesses, as he did by saying hello to one. The development occurred shortly after jurors heard opening statements in the trial of Chan and Songjiang Wang, a former Merrimack Pharmaceuticals Inc (MACK.O) employee who prosecutors say participated in the insider trading scheme with Chan.